Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological restoration of GTP hydrolysis by mutant RAS.

Nature - 1 Jan 2025

Cuevas-Navarro Antonio, Pourfarjam Yasin, Hu Feng, Rodriguez Diego J, Vides Alberto, Sang Ben, Fan Shijie, Goldgur Yehuda, de Stanchina Elisa, Lito Piro

Abstract excerpt

Approximately 3.4 million patients worldwide are diagnosed each year with cancers that have pathogenic mutations in one of three RAS proto-oncogenes (KRAS, NRAS and HRAS)1,2. These mutations impair the GTPase activity of RAS, leading to activation of downstream signalling and proliferation3-6. Long-standing efforts to restore the hydrolase activity of RAS mutants have been unsuccessful, extinguishing any...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Guanosine Triphosphate

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hydrolysis

Share to Mutant Proteins

Share to Mutation

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39476862
DOI: 10.1038/s41586-024-08283-2
PMCID: PMC11666464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological restoration of GTP hydrolysis by mutant RAS.PMID 39476862Read ↗

Disrupted molecular glue complex drives RAS inhibitor resistance.Semantic proximity Read ↗

Brønsted-basic small molecules activate GTP hydrolysis in Ras Q61 mutantsSemantic proximity Read ↗

Mechanisms of resistance to active state selective tri-complex RAS inhibitorsSemantic proximity Read ↗

Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven CancersSemantic proximity Read ↗

Small-molecule modulation of Ras signaling.Semantic proximity Read ↗

The Neomorphic Chemistry of KRAS Autophosphorylation Is Dynamically Regulated by Active Site Conformation.Semantic proximity Read ↗

Small molecule inhibitors of RAS proteins with oncogenic mutations.Semantic proximity Read ↗

Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Semantic proximity Read ↗

Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61LSemantic proximity Read ↗

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.Semantic proximity Read ↗

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.Semantic proximity Read ↗

Developing Small Molecules that Inhibit K-Ras/GTP Binding Based on New Affinity MeasurementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.